Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) insider Khurram Jamil sold 13,654 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $0.88, for a total transaction of $12,015.52. Following the completion of the transaction, the insider now owns 26,346 shares of the company's stock, valued at $23,184.48. This trade represents a 34.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Galectin Therapeutics Price Performance
NASDAQ GALT opened at $0.87 on Friday. Galectin Therapeutics Inc. has a 12 month low of $0.73 and a 12 month high of $4.27. The company has a market capitalization of $54.61 million, a P/E ratio of -1.19 and a beta of 0.69. The company's 50 day simple moving average is $2.37 and its 200 day simple moving average is $2.44.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of GALT. JPMorgan Chase & Co. grew its holdings in shares of Galectin Therapeutics by 161.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 30,628 shares of the company's stock worth $84,000 after acquiring an additional 18,907 shares during the last quarter. Barclays PLC boosted its position in shares of Galectin Therapeutics by 309.0% in the 3rd quarter. Barclays PLC now owns 28,587 shares of the company's stock valued at $79,000 after purchasing an additional 21,598 shares during the period. Soltis Investment Advisors LLC purchased a new position in Galectin Therapeutics in the 3rd quarter worth about $387,000. Geode Capital Management LLC raised its holdings in Galectin Therapeutics by 2.5% during the 3rd quarter. Geode Capital Management LLC now owns 862,542 shares of the company's stock worth $2,372,000 after buying an additional 20,817 shares during the period. Finally, Kovitz Investment Group Partners LLC purchased a new stake in Galectin Therapeutics during the third quarter valued at about $117,000. Institutional investors own 11.68% of the company's stock.
Wall Street Analysts Forecast Growth
Trading 5-7 Stocks to Profit $1,300 a Day?
From Prosper Trading Academy | Ad
If you want a straightforward, faster, and potentially more reliable way to trade…
Learn this strategy by watching this brand new video presentation
Click here to learn the 5-Stock Formula that could potentially boost your profit potential.
A number of equities analysts have issued reports on GALT shares. StockNews.com raised Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. HC Wainwright reaffirmed a "buy" rating and set a $11.00 target price on shares of Galectin Therapeutics in a research note on Friday, November 15th.
Read Our Latest Research Report on GALT
Galectin Therapeutics Company Profile
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
